04/03/2026
Type 2 Diabetes
• Reviews of clinical data report that ≈70% of T2DM patients saw significant improvements in glucose control and reduced medication needs after mesenchymal stem cell (MSC) therapy.
Type 1 Diabetes
• In an early clinical trial using stem-cell-derived islet cells, 10 out of 12 participants (~83%) became insulin independent for at least 12 months after treatment.
Important Reminders!
• Outcomes depend on protocol, patient selection, and disease stage.
If you want to learn more, message us for free phone call consultation